Advertisement

Evaluation of cytotoxicity and antiviral activity of recombinant human interferon alfa-2a and recombinant human interferon alfa-B/D hybrid against bovine viral diarrhea virus, infectious bovine rhinotracheitis virus, and vesicular stomatitis virus in vitro

Simon F. PeekDepartment of Medical Sciences , School of Veterinary Medicine, University of Wisconsin, Madison, WI 53706.

Search for other papers by Simon F. Peek in
Current site
Google Scholar
PubMed
Close
 BVSc, PhD
,
Michael D. BondsDepartment of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin, Madison, WI 53706.

Search for other papers by Michael D. Bonds in
Current site
Google Scholar
PubMed
Close
 BS
,
David G. GangemiInstitute for Nutraceutical Research, Clemson University, Clemson, SC 29634.

Search for other papers by David G. Gangemi in
Current site
Google Scholar
PubMed
Close
 PhD
,
Chester B. ThomasDepartment of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin, Madison, WI 53706.

Search for other papers by Chester B. Thomas in
Current site
Google Scholar
PubMed
Close
 PhD, DVM
, and
Ronald D. SchultzDepartment of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin, Madison, WI 53706.

Search for other papers by Ronald D. Schultz in
Current site
Google Scholar
PubMed
Close
 PhD

Abstract

Objective—To evaluate cytotoxicity and antiviral activity of recombinant human interferon alfa-2a and recombinant human interferon alfa-B/D hybrid against cytopathic and noncytopathic bovine viral diarrhea virus (BVDV), infectious bovine rhinotracheitis virus (IBRV), and vesicular stomatitis virus (VSV) in vitro.

Sample population—Primary bovine testicular cells and Mardin Darby bovine kidney cells.

Procedures—To evaluate cytotoxicity, cells were added to serial dilutions of each interferon. To evaluate antiviral activity of each interferon, interferons were serially diluted 1:10, and tissue culture cells were added; virus was then added at 3 time points. Prevention of viral infection by interferon was defined as failure to induce cytopathologic effect for VSV, IBRV, and cytopathic BVDV and failure to detect virus immunohistochemically for cytopathic and noncytopathic BVDV.

Results—No evidence of cytotoxicity in either cell line was detected after incubation with interferon alfa- 2a or interferon alfa-B/D. However, reduced growth rates of tissue culture cells were detected for each interferon when undiluted interferon was tested. Comparable and profound antiviral activities against cytopathic and noncytopathic BVDV were evident for each interferon. Interferon alfa-2a and interferon a-B/D had comparable antiviral activities against VSV. Neither interferon had antiviral activity against IBRV.

Conclusions and Clinical Relevance—The safety and marked in vitro antiviral activity against noncytopathic BVDV, cytopathic BVDV, and VSV suggest that interferons alfa-2a and alfa-B/D may be useful for treatment of natural disease after infection with these viruses. (Am J Vet Res 2004;65:871–874)

Abstract

Objective—To evaluate cytotoxicity and antiviral activity of recombinant human interferon alfa-2a and recombinant human interferon alfa-B/D hybrid against cytopathic and noncytopathic bovine viral diarrhea virus (BVDV), infectious bovine rhinotracheitis virus (IBRV), and vesicular stomatitis virus (VSV) in vitro.

Sample population—Primary bovine testicular cells and Mardin Darby bovine kidney cells.

Procedures—To evaluate cytotoxicity, cells were added to serial dilutions of each interferon. To evaluate antiviral activity of each interferon, interferons were serially diluted 1:10, and tissue culture cells were added; virus was then added at 3 time points. Prevention of viral infection by interferon was defined as failure to induce cytopathologic effect for VSV, IBRV, and cytopathic BVDV and failure to detect virus immunohistochemically for cytopathic and noncytopathic BVDV.

Results—No evidence of cytotoxicity in either cell line was detected after incubation with interferon alfa- 2a or interferon alfa-B/D. However, reduced growth rates of tissue culture cells were detected for each interferon when undiluted interferon was tested. Comparable and profound antiviral activities against cytopathic and noncytopathic BVDV were evident for each interferon. Interferon alfa-2a and interferon a-B/D had comparable antiviral activities against VSV. Neither interferon had antiviral activity against IBRV.

Conclusions and Clinical Relevance—The safety and marked in vitro antiviral activity against noncytopathic BVDV, cytopathic BVDV, and VSV suggest that interferons alfa-2a and alfa-B/D may be useful for treatment of natural disease after infection with these viruses. (Am J Vet Res 2004;65:871–874)